US · Healthcare · Biotechnology
EPS came in at 0.05 against a street estimate of 0.03 — a beat of 66.7%.
Analysts rate Caris Life Sciences, Inc. Common Stock a buy (10 buy, 4 hold, 0 sell out of 14) with an average price target of $32.46.
CONFIDENT Caris delivered record Q2 volume (+18% YoY, 59,200 cases) driven by commercial reorganization gains. Raised FY26 revenue guidance to $1.03–1.04B (+27–28% growth). Launching Detect early-detection test, MRD assay, and MI Clarity V2 to expand market reach. Q2 2026 No geographic breakdown provided. Analysts probed volume acceleration drivers (sales maturation), new product timing (Detect excluded from guidance pending 1–2 quarters history), and competitive positioning (Brian emphasized secular adoption of comprehensive vs. narrow panels). Management confident in back-half momentum but cautious on quantifying new launches until proven. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 10.94% |
| J. H. Whitney Equity Partners VI, LLC | 3.98% |
| Coatue Management LLC | 3.47% |
| BRAIDWELL LP | 2.92% |
| Sixth Street Partners Management Company, L.P. | 2.59% |
| PointState Capital LP | 2.42% |
| JPMorgan Chase & Co | 2.32% |
| BlackRock Inc | 1.96% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $275.358 million, up from $216.833 million in the third quarter of 2025. • Nine-month 2026 revenue | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $275.4 million, up 27% from $216.8 million in the third quarter of 2025. • Molecular profiling ser | 2026-11-04 |
| Reg FD disclosure · Q3 2026 CARIS LIFE SCIENCES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial data disclosed – This Form 8-K contains no quantitative results, earnin | 2026-09-14 |
| Quarterly report · Q2 2026 CARIS LIFE SCIENCES, INC. – FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total Revenue (6 months 2026): $479,886 thousa | 2026-08-05 |
| Results announced · Q3 2026 CARIS LIFE SCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $263.7 million, up 45% year-over-year (vs. $181.4 mi | 2026-08-05 |
| Shareholder vote results · Q2 2026 CARIS LIFE SCIENCES, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 4, 2026 • 282,662,545 total shares outstanding | 2026-06-05 |
| Quarterly report · Q1 2026 CARIS LIFE SCIENCES, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Total Revenue: $216.2 million (up 79% from $120.9 million in Q1 2025) | 2026-05-08 |
| Results announced · Q2 2026 CARIS LIFE SCIENCES Q1 2026 FINANCIAL RESULTS HEADLINE NUMBERS • Total revenue: $216.2 million, up 79% year-over-year (prior year: $120.9 million) • | 2026-05-07 |
Readable in the app.
| Announcement | Date |
|---|---|
| Raised 2026 revenue guidance to $1.04–$1.05 billion Caris Life Sciences reported a strong third quarter operationally, with revenue up 27% year over year to $275.4 million. Molecular profiling services revenue also rose 27% to $262.7 million, | 2026-11-04 |
| Raises 2026 revenue guidance to $1.03-$1.04 billion, representing 27-28% growth Caris Life Sciences reported strong Q2 2026 results with 45% revenue growth to $263.7 million, driven by increased molecular profiling services. The company processed approximately 59,200 cl | 2026-08-05 |
| Full year 2026 revenue guidance provided: $1.0-1.02 billion range Caris Life Sciences, a precision medicine company, reported exceptional financial results for 2025. The company achieved 97% full-year revenue growth to $812 million, driven by strong demand | 2026-02-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Caris Life Sciences, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.